Development and Challenges of Cyclic Peptides for Immunomodulation


Cite item

Full Text

Abstract

Cyclic peptides are polypeptide chains formed by cyclic sequences of amide bonds between protein-derived or non-protein-derived amino acids. Compared to linear peptides, cyclic peptides offer several unique advantages, such as increased stability, stronger affinity, improved selectivity, and reduced toxicity. Cyclic peptide has been proved to have a promising application prospect in the medical field. In addition, this paper mainly describes that cyclic peptides play an important role in anti-cancer, anti-inflammatory, anti-virus, treatment of multiple sclerosis and membranous nephropathy through immunomodulation. In order to know more useful information about cyclic peptides in clinical research and drug application, this paper also summarizes cyclic peptides currently in the clinical trial stage and cyclic peptide drugs approved for marketing in the recent five years. Cyclic peptides have many advantages and great potential in treating various diseases, but there are still many challenges to be solved in the development process of cyclic peptides. about cyclic peptides in clinical research and drug application, this paper also summarizes cyclic peptides currently in the clinical trial stage and cyclic peptide drugs approved for marketing in the recent five years. Cyclic peptides have many advantages and great potential in treating various diseases, but there are still many challenges to be solved in the development process of cyclic peptides.

About the authors

Xianqiong Jiang

School of Pharmacy and Bioengineering, Chongqing University of Technology

Email: info@benthamscience.net

Li Gao

School of Pharmacy and Bioengineering, Chongqing University of Technology

Email: info@benthamscience.net

Zhilong Li

School of Pharmacy and Bioengineering, Chongqing University of Technology

Email: info@benthamscience.net

Yan Shen

School of Pharmacy and Bioengineering, Chongqing University of Technology

Email: info@benthamscience.net

Zhi-Hua Lin

School of Pharmacy and Bioengineering, Chongqing University of Technology

Author for correspondence.
Email: info@benthamscience.net

References

  1. Muttenthaler, M.; King, G.F.; Adams, D.J.; Alewood, P.F. Trends in peptide drug discovery. Nat. Rev. Drug Discov., 2021, 20(4), 309-325. doi: 10.1038/s41573-020-00135-8 PMID: 33536635
  2. Abdalla, M.; McGaw, L. Natural cyclic peptides as an attractive modality for therapeutics: A mini review. Molecules, 2018, 23(8), 2080-2198. doi: 10.3390/molecules23082080 PMID: 30127265
  3. Bellavita, R.; Maione, A.; Merlino, F.; Siciliano, A.; Dardano, P.; De Stefano, L.; Galdiero, S.; Galdiero, E.; Grieco, P.; Falanga, A. Antifungal and antibiofilm activity of cyclic temporin L peptide analogues against albicans and non-albicans candida species. Pharmaceutics, 2022, 14(2), 454-478. doi: 10.3390/pharmaceutics14020454 PMID: 35214187
  4. (a) Bajraktari-Sylejmani, G.; Von Linde, T.; Burhenne, J.; Haefeli, W.E.; Sauter, M.; Weiss, J. Evaluation of pept1 (slC15A1) substrate characteristics of therapeutic cyclic peptides. Pharmaceutics, 2022, 14(8), 1610-1620. doi: 10.3390/pharmaceutics14081610 PMID: 36015235; (b) Horton, D.A.; Bourne, G.T.; Smythe, M.L. Exploring privileged structures: the combinatorial synthesis of cyclic peptides. J. Comput. Aided Mol. Des., 2002, 16(5/6), 415-431. doi: 10.1023/A:1020863921840 PMID: 12489688; (c) Furman, O.; Zaporozhets, A.; Tobi, D.; Bazylevich, A.; Firer, M.A.; Patsenker, L.; Gellerman, G.; Lubin, B.C.R. Novel cyclic peptides for targeting EGFR and EGRvIII mutation for drug delivery. Pharmaceutics, 2022, 14(7), 1505-1522. doi: 10.3390/pharmaceutics14071505 PMID: 35890400; (d) Gallo, M.; Defaus, S.; Andreu, D. Disrupting GPCR complexes with smart drug-like peptides. Pharmaceutics, 2022, 14(1), 161-177. doi: 10.3390/pharmaceutics14010161 PMID: 35057055
  5. Yang, L.; Tan, R.; Wang, Q.; Huang, W.; Yin, Y. Antifungal cyclopeptides from halobacillus litoralis ys3106 of marine origin. Tetrahedron Lett., 2002, 43(37), 6545-6548. doi: 10.1016/S0040-4039(02)01458-2
  6. Jiang, L.; Huang, P.; Ren, B.; Song, Z.; Zhu, G.; He, W.; Zhang, J.; Oyeleye, A.; Dai, H.; Zhang, L.; Liu, X. Antibacterial polyene-polyol macrolides and cyclic peptides from the marine-derived Streptomyces sp. MS110128. Appl. Microbiol. Biotechnol., 2021, 105(12), 4975-4986. doi: 10.1007/s00253-021-11226-w PMID: 34146138
  7. Karim, M.R.U.; In, Y.; Zhou, T.; Harunari, E.; Oku, N.; Igarashi, Y. Nyuzenamides A and B: Bicyclic peptides with antifungal and cytotoxic activity from a marine-derived streptomyces sp. Org. Lett., 2021, 23(6), 2109-2113. doi: 10.1021/acs.orglett.1c00210 PMID: 33661652
  8. Muratspahić, E.; Tomašević, N.; Nasrollahi-Shirazi, S.; Gattringer, J.; Emser, F.S.; Freissmuth, M.; Gruber, C.W. Plant-Derived cyclotides modulate κ-opioid receptor signaling. J. Nat. Prod., 2021, 84(8), 2238-2248. doi: 10.1021/acs.jnatprod.1c00301 PMID: 34308635
  9. (a) Du, Q.; Huang, Y.H.; Bajpai, A.; Frosig- Jorgensen, M.; Zhao, G.; Craik, D.J. Evaluation of the in vivo Aphrodisiac Activity of a Cyclotide Extract from Hybanthus enneaspermus. J. Nat. Prod., 2020, 83(12), 3736-3743. doi: 10.1021/acs.jnatprod.0c01045 PMID: 33296204; (b) Fahradpour, M.; Keov, P.; Tognola, C.; Perez-Santamarina, E.; McCormick, P.J.; Ghassempour, A.; Gruber, C.W. Cyclotides isolated from an ipecac root extract antagonize the corticotropin releasing factor type 1 receptor. Front. Pharmacol., 2017, 8, 616-629. doi: 10.3389/fphar.2017.00616 PMID: 29033832; (c) Anastasiou, E.; Lorentz, K.O.; Stein, G.J.; Mitchell, P.D. Prehistoric schistosomiasis parasite found in the middle east. Lancet Infect. Dis., 2014, 14(7), 553-554. doi: 10.1016/S1473-3099(14)70794-7 PMID: 24953264
  10. Abdalla, M.A. Three new cyclotetrapeptides isolated from streptomyces sp. 447. Nat. Prod. Res., 2017, 31(9), 1014-1021. doi: 10.1080/14786419.2016.1263849 PMID: 27936924
  11. Wyche, T.P.; Ruzzini, A.C.; Schwab, L.; Currie, C.R.; Clardy, J.; Tryptorubin, A. Tryptorubin A: A polycyclic peptide from a fungus-derived streptomycete. J. Am. Chem. Soc., 2017, 139(37), 12899-12902. doi: 10.1021/jacs.7b06176 PMID: 28853867
  12. Liang, X.; Nong, X.H.; Huang, Z.H.; Qi, S.H. Antifungal and antiviral cyclic peptides from the deep-sea-derived fungus simplicillium obclavatum EIODSF 020. J. Agric. Food Chem., 2017, 65(25), 5114-5121. doi: 10.1021/acs.jafc.7b01238 PMID: 28578573
  13. Zhou, T.; Katsuragawa, M.; Xing, T.; Fukaya, K.; Okuda, T.; Tokiwa, T.; Tashiro, E.; Imoto, M.; Oku, N.; Urabe, D.; Igarashi, Y. Cyclopeptides from the mushroom pathogen fungus cladobotryum varium. J. Nat. Prod., 2021, 84(2), 327-338. doi: 10.1021/acs.jnatprod.0c00980 PMID: 33439652
  14. Takashina, K.; Katsuyama, A.; Kaguchi, R.; Yamamoto, K.; Sato, T.; Takahashi, S.; Horiuchi, M.; Yokota, S.; Ichikawa, S. Solid-phase total synthesis of plusbacin A3. Org. Lett., 2022, 24(11), 2253-2257. doi: 10.1021/acs.orglett.2c00667 PMID: 35293208
  15. Ullrich, S.; George, J.; Coram, A.E.; Morewood, R.; Nitsche, C. Biocompatible and selective generation of bicyclic peptides. Angew. Chem. Int. Ed., 2022, 61(43), e202208400. doi: 10.1002/anie.202208400 PMID: 35852030
  16. Marciniak, A.; Pacini, L.; Papini, A.M.; Brasuń, J. Bicyclopeptides: a new class of ligands for Cu( II ) ions. Dalton Trans., 2022, 51(35), 13368-13375. doi: 10.1039/D2DT01497A PMID: 35984441
  17. Yates, N.D.J.; Warnes, M.E.; Breetveld, R.; Spicer, C.D.; Signoret, N.; Fascione, M. Preparation and application of an inexpensive α-formylglycine building block compatible with fmoc solid-phase peptide synthesis. Org. Lett., 2023, 25(12), 2001-2005. doi: 10.1021/acs.orglett.2c04059 PMID: 36662590
  18. Nagaya, A.; Murase, S.; Mimori, Y.; Wakui, K.; Yoshino, M.; Matsuda, A.; Kobayashi, Y.; Kurasaki, H.; Cary, D.R.; Masuya, K.; Handa, M.; Nishizawa, N. Extended solution-phase peptide synthesis strategy using isostearyl-mixed anhydride coupling and a new C-terminal silyl ester-protecting group for N -methylated cyclic peptide production. Org. Process Res. Dev., 2021, 25(9), 2029-2038. doi: 10.1021/acs.oprd.1c00078
  19. Li, H.; Li, J.; Chao, J.; Zhang, Z.; Qin, C. Total liquid-phase sythesis, head-to-tail cyclization and synergistic self-cleavage of peptide on small-molecular supports. ChemRxiv, 2021, 2021
  20. Hossain, F.; Nishat, S.; Andreana, P.R. Synthesis of malformin-A 1, C, a glycan, and an aglycon analog: Potential scaffolds for targeted cancer therapy. Pept. Sci., 2022, 114(4), e24260. doi: 10.1002/pep2.24260
  21. Kanwal, I.; Mushtaq, F.; Ali, H.; Tufail, P.; Jahan, H.; Shaheen, F. First report on the synthesis and structural studies of trans-Phakellistatin 18: A rotamer of marine natural product phakellistatin 18. Nat. Prod. Res., 2023, 37(9), 1470-1479. doi: 10.1080/14786419.2021.2023141 PMID: 34986732
  22. Yayat, H.N.A.; Maharani, R.; Hidayat, A.T.; Wiani, I.; Zainuddin, A.; Mayanti, T.; Nurlelasari; Harneti, D.; Supratman, U. Total synthesis of a reversed cyclopurpuracin using a combination of solid and solution phase methods. J. Heterocycl. Chem., 2022, 59(11), 1963-1970. doi: 10.1002/jhet.4532
  23. Napitupulu, O.I.; Sumiarsa, D.; Subroto, T.; Nurlelasari; Harneti, D.; Supratman, U.; Maharani, R. Synthesis of cyclo-PLAI using a combination of solid- and solution-phase methods. Synth. Commun., 2019, 49(2), 308-315. doi: 10.1080/00397911.2018.1554148
  24. Wills, R.; Adebomi, V.; Raj, M. Site-selective peptide macrocyclization. ChemBioChem, 2021, 22(1), 52-62. doi: 10.1002/cbic.202000398 PMID: 32794268
  25. Raj, M.; Wills, R.D.; Adebomi, V.T. Peptide cyclization at high concentration. Synlett, 2020, 31(16), 1537-1542. doi: 10.1055/s-0040-1707165
  26. Wills, R.; Adebomi, V.; Spancake, C.; Cohen, R.D.; Raj, M. Synthesis of L-cyclic tetrapeptides by backbone amide activation CyClick strategy. Tetrahedron, 2022, 126, 133071-133076. doi: 10.1016/j.tet.2022.133071
  27. Habibi, Y.; Weerasinghe, N.W.; Uggowitzer, K.A.; Thibodeaux, C.J. Partially modified peptide intermediates in lanthipeptide biosynthesis alter the structure and dynamics of a lanthipeptide synthetase. J. Am. Chem. Soc., 2022, 144(23), 10230-10240. doi: 10.1021/jacs.2c00727 PMID: 35647706
  28. (a) Rice, A.J.; Pelton, J.M.; Kramer, N.J.; Catlin, D.S.; Nair, S.K.; Pogorelov, T.V.; Mitchell, D.A.; Bowers, A.A. Enzymatic pyridine aromatization during thiopeptide biosynthesis. J. Am. Chem. Soc., 2022, 144(46), 21116-21124. doi: 10.1021/jacs.2c07377 PMID: 36351243; (b) Nguyen, D.T.; Le, T.T.; Rice, A.J.; Hudson, G.A.; Van der Donk, W.A.; Mitchell, D.A. Accessing diverse pyridine-based macrocyclic peptides by a two-site recognition pathway. J. Am. Chem. Soc., 2022, 144(25), 11263-11269. doi: 10.1021/jacs.2c02824 PMID: 35713415
  29. Kersten, R.D.; Mydy, L.S.; Fallon, T.R.; de Waal, F.; Shafiq, K.; Wotring, J.W.; Sexton, J.Z.; Weng, J.K. Gene-guided discovery and ribosomal biosynthesis of moroidin peptides. J. Am. Chem. Soc., 2022, 144(17), 7686-7692. doi: 10.1021/jacs.2c00014 PMID: 35438481
  30. Sugiyama, R.; Suarez, A.F.L.; Morishita, Y.; Nguyen, T.Q.N.; Tooh, Y.W.; Roslan, M.N.H.B.; Lo Choy, J.; Su, Q.; Goh, W.Y.; Gunawan, G.A.; Wong, F.T.; Morinaka, B.I. The biosynthetic landscape of triceptides reveals radical sam enzymes that catalyze cyclophane formation on tyr- and his-containing motifs. J. Am. Chem. Soc., 2022, 144(26), 11580-11593. doi: 10.1021/jacs.2c00521 PMID: 35729768
  31. Luo, J.; Liu, S.; Lu, H.; Chen, Q.; Shi, Y. A comprehensive review of microorganism-derived cyclic peptides: Bioactive functions and food safety applications. Compr. Rev. Food Sci. Food Saf., 2022, 21(6), 5272-5290. doi: 10.1111/1541-4337.13038 PMID: 36161470
  32. Kazmaier, U.; Junk, L. Recent developments on the synthesis and bioactivity of ilamycins/rufomycins and cyclomarins, marine cyclopeptides that demonstrate anti-malaria and anti-tuberculosis activity. Mar. Drugs, 2021, 19(8), 446-472. doi: 10.3390/md19080446 PMID: 34436284
  33. Kazemi Shariat Panahi, H.; Mohammadipanah, F.; Rahmati, F.; Tarlani, A.; Hamedi, J. In situ recovery of persipeptides from streptomyces zagrosensis fermentation broth by enhanced adsorption. Iran. J. Biotechnol., 2020, 18(2), e2231-e2240. PMID: 33542931
  34. Helaly, S.E.; Hamad, Z.; El Sayed, M.A.; Abdel-Motaal, F.F.; Nassar, M.I.; Ito, S.; Stadler, M. Bacillus methylotrophicus ASWU-C2, a strain inhabiting hot desert soil, a new source for antibacterial bacillopyrone, pyrophen, and cyclopeptides. Z. Naturforsch. C J. Biosci., 2018, 74(1-2), 55-59. doi: 10.1515/znc-2018-0093 PMID: 30864389
  35. (a) Zhao, L.; Wei, L.; Li, X.; Chen, H.; Liu, J.; Wang, X.; Guan, F. Design and synthesis of novel cyclopeptide p53-MDM2 inhibitors with isoindolinone as antitumor agent. J. Mol. Struct., 2023, 1275, 134604-134610. doi: 10.1016/j.molstruc.2022.134604; (b) Xiao, S.; Wang, Z.; Zhang, H.; Zhao, L.; Chang, Q.; Zhang, X.; Yan, R.; Wu, X.; Jin, Y. Photoinduced synthesis of methylated marine cyclopeptide galaxamide analogs with isoindolinone as anticancer agents. Mar. Drugs, 2022, 20(6), 379-399. doi: 10.3390/md20060379 PMID: 35736182; (c) Jiang, S.; Zhao, L.; Wu, J.; Bao, Y.; Wang, Z.; Jin, Y. Photo-induced synthesis, structure and in vitro bioactivity of a natural cyclic peptide Yunnanin A analog. RSC Advances, 2020, 10(1), 210-214. doi: 10.1039/C9RA09163G PMID: 35492554; (d) Zhang, H.; Wu, J.; Wang, J.; Xiao, S.; Zhao, L.; Yan, R.; Wu, X.; Wang, Z.; Fan, L.; Jin, Y. Novel Isoindolinone-based analogs of the natural cyclic peptide fenestin A: Synthesis and antitumor activity. ACS Med. Chem. Lett., 2022, 13(7), 1118-1124. doi: 10.1021/acsmedchemlett.2c00149 PMID: 35859879; (e) Bao, Y.; Zhao, L.; Wu, J.; Jiang, S.; Wang, Z.; Jin, Y. Photo-induced synthesis of Axinastatin 3 analogs, the secondary structures and their in vitro antitumor activities. Bioorg. Med. Chem. Lett., 2019, 29(22), 126730-126734. doi: 10.1016/j.bmcl.2019.126730 PMID: 31607609
  36. (a) Zhang, J.N.; Xia, Y.X.; Zhang, H.J. Natural cyclopeptides as anticancer agents in the last 20 years. Int. J. Mol. Sci., 2021, 22(8), 3973-4030. doi: 10.3390/ijms22083973 PMID: 33921480; (b) Zhao, K.; Xing, R.; Yan, X. Cyclic dipeptides: Biological activities and self-assembled materials. Pept. Sci., 2021, 113(2), e24202-e24214. doi: 10.1002/pep2.24202; (c) Jwad, R.; Weissberger, D.; Hunter, L. Strategies for fine-tuning the conformations of cyclic peptides. Chem. Rev., 2020, 120(17), 9743-9789. doi: 10.1021/acs.chemrev.0c00013 PMID: 32786420; (d) Chow, H.Y.; Zhang, Y.; Matheson, E.; Li, X. Ligation technologies for the synthesis of cyclic peptides. Chem. Rev., 2019, 119(17), 9971-10001. doi: 10.1021/acs.chemrev.8b00657 PMID: 31318534; (e) Malde, A.K.; Hill, T.A.; Iyer, A.; Fairlie, D.P. Crystal structures of protein-bound cyclic peptides. Chem. Rev., 2019, 119(17), 9861-9914. doi: 10.1021/acs.chemrev.8b00807 PMID: 31046237; (f) Nielsen, D.S.; Shepherd, N.E.; Xu, W.; Lucke, A.J.; Stoermer, M.J.; Fairlie, D.P. Orally absorbed cyclic peptides. Chem. Rev., 2017, 117(12), 8094-8128. doi: 10.1021/acs.chemrev.6b00838 PMID: 28541045; (g) Dougherty, P.G.; Sahni, A.; Pei, D. Understanding cell penetration of cyclic peptides. Chem. Rev., 2019, 119(17), 10241-10287. doi: 10.1021/acs.chemrev.9b00008 PMID: 31083977; (h) Zorzi, A.; Deyle, K.; Heinis, C. Cyclic peptide therapeutics: Past, present and future. Curr. Opin. Chem. Biol., 2017, 38, 24-29. doi: 10.1016/j.cbpa.2017.02.006 PMID: 28249193
  37. Räder, A.F.B.; Reichart, F.; Weinmüller, M.; Kessler, H. Improving oral bioavailability of cyclic peptides by N-methylation. Bioorg. Med. Chem., 2018, 26(10), 2766-2773. doi: 10.1016/j.bmc.2017.08.031 PMID: 28886995
  38. Iskandarsyah; Tejo, B.A.; Tambunan, U.S.F.; Verkhivker, G.; Siahaan, T.J. Structural modifications of ICAM-1 cyclic peptides to improve the activity to inhibit heterotypic adhesion of T cells. Chem. Biol. Drug Des., 2008, 72(1), 27-33. doi: 10.1111/j.1747-0285.2008.00676.x PMID: 18554252
  39. Tang, J.; He, Y.; Chen, H.; Sheng, W.; Wang, H. Synthesis of bioactive and stabilized cyclic peptides by macrocyclization using C(sp3)–H activation. Chem. Sci., 2017, 8(6), 4565-4570. doi: 10.1039/C6SC05530C PMID: 28936334
  40. Ulapane, K.R.; Kopec, B.M.; Siahaan, T.J. Improving in vivo brain delivery of monoclonal antibody using novel cyclic peptides. Pharmaceutics, 2019, 11(11), 568-582. doi: 10.3390/pharmaceutics11110568 PMID: 31683745
  41. Kumar, S.; Mandal, D.; El-Mowafi, S.A.; Mozaffari, S.; Tiwari, R.K.; Parang, K. Click-free synthesis of a multivalent tricyclic peptide as a molecular transporter. Pharmaceutics, 2020, 12(9), 842-858. doi: 10.3390/pharmaceutics12090842 PMID: 32899170
  42. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 1997, 23(1-3), 3-25.
  43. Wang, H.M.; Seo, C.D.; Lee, K.J.; Park, J.H.; Lim, H.S. Evaluation of the cell permeability of bicyclic peptoids and bicyclic peptide-peptoid hybrids. Bioorg. Chem., 2022, 127, 105976-105983. doi: 10.1016/j.bioorg.2022.105976 PMID: 35777233
  44. Riniker, S.; Zurich, E. Toward the elucidation of the mechanism for passive membrane permeability of cyclic peptides. Future Med. Chem., 2019, 11(7), 637-639. doi: 10.4155/fmc-2018-0429 PMID: 30920310
  45. Linker, S.M.; Schellhaas, C.; Ries, B.; Roth, H.J.; Fouché, M.; Rodde, S.; Riniker, S. Polar/apolar interfaces modulate the conformational behavior of cyclic peptides with impact on their passive membrane permeability. RSC Advances, 2022, 12(10), 5782-5796. doi: 10.1039/D1RA09025A PMID: 35424539
  46. Ono, T.; Tabata, K.V.; Goto, Y.; Saito, Y.; Suga, H.; Noji, H.; Morimoto, J.; Sando, S. Label-free quantification of passive membrane permeability of cyclic peptides across lipid bilayers: Penetration speed of cyclosporin A across lipid bilayers. Chem. Sci., 2023, 14(2), 345-349. doi: 10.1039/D2SC05785A PMID: 36687349
  47. Peraro, L.; Kritzer, J.A. Emerging methods and design principles for cell-penetrant peptides. Angew. Chem. Int. Ed., 2018, 57(37), 11868-11881. doi: 10.1002/anie.201801361 PMID: 29740917
  48. Salim, H.; Pei, D. Assessing the cellular uptake, endosomal escape, and cytosolic entry efficiencies of cyclic peptides. Methods Mol. Biol., 2022, 2371(16), 301-316. doi: 10.1007/978-1-0716-1689-5_16 PMID: 34596855
  49. Levi, B.; Yacobovich, S.; Kirby, M.; Becker, M.; Agranyoni, O.; Redko, B.; Gellerman, G.; Pinhasov, A.; Koman, I.; Nesher, E. Anti-cancer effects of cyclic peptide ALOS4 in a human melanoma mouse model. Int. J. Mol. Sci., 2021, 22(17), 9579-9585. doi: 10.3390/ijms22179579 PMID: 34502483
  50. Ramadhani, D.; Maharani, R.; Gazzali, A.M.; Muchtaridi, M. Cyclic peptides for the treatment of cancers: A review. Molecules, 2022, 27(14), 4428. doi: 10.3390/molecules27144428 PMID: 35889301
  51. Pinto, M.E.F.; Najas, J.Z.G.; Magalhães, L.G.; Bobey, A.F.; Mendonça, J.N.; Lopes, N.P.; Leme, F.M.; Teixeira, S.P.; Trovó, M.; Andricopulo, A.D.; Koehbach, J.; Gruber, C.W.; Cilli, E.M.; Bolzani, V.S. Inhibition of breast cancer cell migration by cyclotides isolated from pombalia calceolaria. J. Nat. Prod., 2018, 81(5), 1203-1208. doi: 10.1021/acs.jnatprod.7b00969 PMID: 29757646
  52. Du, X.; Xiao, S.; Luo, Q.; Liu, X.; Liu, J. Laminaria japonica cyclic peptides exert anti-colorectal carcinoma effects through apoptosis induction in vitro and in vivo. J. Pept. Sci., 2022, 28(5), e3385-e3394. doi: 10.1002/psc.3385 PMID: 34935253
  53. Li, D.; Liao, X.; Zhong, S.; Zhao, B.; Xu, S. Synthesis of marine cyclopeptide galaxamide analogues as potential anticancer agents. Mar. Drugs, 2022, 20(3), 158-169. doi: 10.3390/md20030158 PMID: 35323457
  54. Suresh, K.; Abhishek, T.; Varsha, T.; Sukhbir Lal, K.; Renu, S.; Manish, K.; Ajay, S.; Tarun, V.; Reshu, V.; Girish, K.; Abdulsalam, A. Synthesis, anticancer, and antimicrobial evaluation of integerrimide-A. BioMed Res. Int., 2022.
  55. S, R.; S, P.; Joann, M.D.; S, J. Evaluation of anti-inflammatory efficacy of RA-V: A natural cyclopeptide. Appl. Biochem. Biotechnol., 2020, 190(2), 732-744. doi: 10.1007/s12010-019-03124-9 PMID: 31482289
  56. Liu, J.; Wang, H.; Wang, G.; Luo, Q.; Cao, H.; Liu, X.; Zhang, Z.; Yang, P.; Liu, Z. Anti-inflammatory potency of Locusta migratoria manilensis cyclopeptides in mast cells and macrophages. RSC Advances, 2019, 9(54), 31296-31305. doi: 10.1039/C9RA06284J PMID: 35527955
  57. Liu, J.; Gu, B.; Yang, L.; Yang, F.; Lin, H. New anti-inflammatory cyclopeptides from a sponge-derived fungus aspergillus violaceofuscus. Front Chem., 2018, 6, 226-233. doi: 10.3389/fchem.2018.00226 PMID: 29963550
  58. (a) Alsaffar, R.M.; Ali, S.; Rashid, S.; Rashid, S.M.; Majid, S.; Rehman, M.U. Immunomodulation: An immune regulatory mechanism in carcinoma therapeutics. Int. Immunopharmacol., 2021, 99, 107984-107996. doi: 10.1016/j.intimp.2021.107984 PMID: 34303999; (b) Yang, Y.; Mao, H.; Chen, L.; Li, L. Targeting signal pathways triggered by cyclic peptides in cancer: Current trends and future challenges. Arch. Biochem. Biophys., 2021, 701, 108776-108790. doi: 10.1016/j.abb.2021.108776 PMID: 33515532
  59. Chia, L.Y.; Kumar, P.V.; Maki, M.A.A.; Ravichandran, G.; Thilagar, S. A Review: The antiviral activity of cyclic peptides. Int. J. Pept. Res. Ther., 2022, 29(1), 7-33. doi: 10.1007/s10989-022-10478-y PMID: 36471676
  60. Park, J.Y.; Yang, S.Y.; Kim, Y.C.; Kim, J.C.; Dang, Q.L.; Kim, J.J.; Kim, I.S. Antiviral peptide from Pseudomonas chlororaphis O6 against tobacco mosaic virus (TMV). J. Korean Soc. Appl. Biol. Chem., 2012, 55(1), 89-94. doi: 10.1007/s13765-012-0015-2
  61. Song, X.; Lu, L.; Passioura, T.; Suga, H. Macrocyclic peptide inhibitors for the protein–protein interaction of Zaire Ebola virus protein 24 and karyopherin alpha 5. Org. Biomol. Chem., 2017, 15(24), 5155-5160. doi: 10.1039/C7OB00012J PMID: 28574091
  62. Lee, B.W.; Quy Ha, T.K.; Park, E.J.; Cho, H.M.; Ryu, B.; Doan, T.P.; Lee, H.J.; Oh, W.K. Melicopteline A–E, unusual cyclopeptide alkaloids with antiviral activity against influenza a virus from melicope pteleifolia. J. Org. Chem., 2021, 86(2), 1437-1447. doi: 10.1021/acs.joc.0c02137 PMID: 33369410
  63. Johansen-Leete, J.; Ullrich, S.; Fry, S.E.; Frkic, R.; Bedding, M.J.; Aggarwal, A.; Ashhurst, A.S.; Ekanayake, K.B.; Mahawaththa, M.C.; Sasi, V.M.; Luedtke, S.; Ford, D.J.; O’Donoghue, A.J.; Passioura, T.; Larance, M.; Otting, G.; Turville, S.; Jackson, C.J.; Nitsche, C.; Payne, R.J. Antiviral cyclic peptides targeting the main protease of SARS-CoV-2. Chem. Sci., 2022, 13(13), 3826-3836. doi: 10.1039/D1SC06750H PMID: 35432913
  64. Smith, C.A.; Hinman, C.L. Evidence that L1AD3, an apoptosis-inducing cyclic peptide, binds a leukemic T-cell membrane protein receptor. Arch. Biochem. Biophys., 2004, 432(1), 88-101. doi: 10.1016/j.abb.2004.08.010 PMID: 15519300
  65. Anderson, M.E.; Yakovleva, T.; Hu, Y.; Siahaan, T.J. Inhibition of ICAM-1/LFA-1-mediated heterotypic T-cell adhesion to epithelial cells: design of ICAM-1 cyclic peptides. Bioorg. Med. Chem. Lett., 2004, 14(6), 1399-1402. doi: 10.1016/j.bmcl.2003.09.100 PMID: 15006370
  66. Chittasupho, C.; Manikwar, P.; Krise, J.P.; Siahaan, T.J.; Berkland, C. cIBR effectively targets nanoparticles to LFA-1 on acute lymphoblastic T cells. Mol. Pharm., 2010, 7(1), 146-155. doi: 10.1021/mp900185u PMID: 19883077
  67. Gründemann, C.; Thell, K.; Lengen, K.; Garcia-Käufer, M.; Huang, Y.H.; Huber, R.; Craik, D.J.; Schabbauer, G.; Gruber, C.W. Cyclotides suppress human T-lymphocyte proliferation by an interleukin 2-dependent mechanism. PLoS One, 2013, 8(6), e68016-e68027. doi: 10.1371/journal.pone.0068016 PMID: 23840803
  68. Pinto, M.E.F.; Chan, L.Y.; Koehbach, J.; Devi, S.; Gründemann, C.; Gruber, C.W.; Gomes, M.; Bolzani, V.S.; Cilli, E.M.; Craik, D.J. Cyclotides from brazilian palicourea sessilis and their effects on human lymphocytes. J. Nat. Prod., 2021, 84(1), 81-90. doi: 10.1021/acs.jnatprod.0c01069 PMID: 33397096
  69. Hazama, D.; Yin, Y.; Murata, Y.; Matsuda, M.; Okamoto, T.; Tanaka, D.; Terasaka, N.; Zhao, J.; Sakamoto, M.; Kakuchi, Y.; Saito, Y.; Kotani, T.; Nishimura, Y.; Nakagawa, A.; Suga, H.; Matozaki, T. Macrocyclic peptide-mediated blockade of the CD47-SIRPα interaction as a potential cancer immunotherapy. Cell Chem. Biol., 2020, 27(9), 1181-1191.e7. doi: 10.1016/j.chembiol.2020.06.008 PMID: 32640189
  70. Karanam, G.; Arumugam, M.K.; Sirpu Natesh, N. Anticancer effect of marine sponge-associated Bacillus pumilus amk1 derived dipeptide cyclo (-Pro-Tyr) in human liver cancer cell line through apoptosis and G2/M phase arrest. Int. J. Pept. Res. Ther., 2020, 26(1), 445-457. doi: 10.1007/s10989-019-09850-2
  71. Karanam, G.; Arumugam, M.K. Reactive oxygen species generation and mitochondrial dysfunction for the initiation of apoptotic cell death in human hepatocellular carcinoma HepG2 cells by a cyclic dipeptide Cyclo(-Pro-Tyr). Mol. Biol. Rep., 2020, 47(5), 3347-3359. doi: 10.1007/s11033-020-05407-5 PMID: 32248385
  72. Magiera-Mularz, K.; Kuska, K.; Skalniak, L.; Grudnik, P.; Musielak, B.; Plewka, J.; Kocik, J.; Stec, M.; Weglarczyk, K.; Sala, D.; Wladyka, B.; Siedlar, M.; Holak, T.A.; Dubin, G. Macrocyclic peptide inhibitor of PD-1/PD-L1 immune checkpoint. Adv. Ther., 2021, 4(2), 2000195-2000200. doi: 10.1002/adtp.202000195
  73. Zhai, W.; Zhou, X.; Zhai, M.; Li, W.; Ran, Y.; Sun, Y.; Du, J.; Zhao, W.; Xing, L.; Qi, Y.; Gao, Y. Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy. Sci. China Life Sci., 2021, 64(4), 548-562. doi: 10.1007/s11427-020-1740-8 PMID: 32737851
  74. Zhai, W.; Zhou, X.; Wang, H.; Li, W.; Chen, G.; Sui, X.; Li, G.; Qi, Y.; Gao, Y. A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses. Acta Pharm. Sin. B, 2020, 10(6), 1047-1060. doi: 10.1016/j.apsb.2020.01.005 PMID: 32642411
  75. Miao, Q.; Zhang, W.; Zhang, K.; Li, H.; Zhu, J.; Jiang, S. Rational design of a potent macrocyclic peptide inhibitor targeting the PD-1/PD-L1 protein–protein interaction. RSC Advances, 2021, 11(38), 23270-23279. doi: 10.1039/D1RA03118J PMID: 35479790
  76. Wang, X.; Hu, C.; Wu, X.; Wang, S.; Zhang, A.; Chen, W.; Shen, Y.; Tan, R.; Wu, X.; Sun, Y.; Xu, Q.; Roseotoxin, B. Roseotoxin B improves allergic contact dermatitis through a unique anti-inflammatory mechanism involving excessive activation of autophagy in activated t lymphocytes. J. Invest. Dermatol., 2016, 136(8), 1636-1646. doi: 10.1016/j.jid.2016.04.017 PMID: 27155460
  77. Shen, Y.; Luo, Q.; Xu, H.; Gong, F.; Zhou, X.; Sun, Y.; Wu, X.; Liu, W.; Zeng, G.; Tan, N.; Xu, Q. Mitochondria-dependent apoptosis of activated T lymphocytes induced by astin C, a plant cyclopeptide, for preventing murine experimental colitis. Biochem. Pharmacol., 2011, 82(3), 260-268. doi: 10.1016/j.bcp.2011.04.013 PMID: 21569765
  78. Wang, Z.; Zhao, S.; Song, L.; Pu, Y.; Wang, Q.; Zeng, G.; Liu, X.; Bai, M.; Li, S.; Gao, F.; Chen, L.; Wang, C.; Tan, N. Natural cyclopeptide RA-V inhibits the NF-κB signaling pathway by targeting TAK1. Cell Death Dis., 2018, 9(7), 715. doi: 10.1038/s41419-018-0743-2 PMID: 29915207
  79. Zou, X.G.; Shim, Y.Y.; Cho, J.Y.; Jeong, D.; Yang, J.; Deng, Z.Y.; Reaney, M.J.T. Flaxseed orbitides, linusorbs, inhibit LPS-induced THP-1 macrophage inflammation. RSC Advances, 2020, 10(38), 22622-22630. doi: 10.1039/C9RA09058D PMID: 35514549
  80. Matsoukas, J.M.; Ligielli, I.; Chasapis, C.T.; Kelaidonis, K.; Apostolopoulos, V.; Mavromoustakos, T. Novel approaches in the immunotherapy of multiple sclerosis: Cyclization of myelin epitope peptides and conjugation with mannan. Brain Sci., 2021, 11(12), 1583-1596. doi: 10.3390/brainsci11121583 PMID: 34942885
  81. Hellinger, R.; Muratspahić, E.; Devi, S.; Koehbach, J.; Vasileva, M.; Harvey, P.J.; Craik, D.J.; Gründemann, C.; Gruber, C.W. Importance of the cyclic cystine knot structural motif for immunosuppressive effects of cyclotides. ACS Chem. Biol., 2021, 16(11), 2373-2386. doi: 10.1021/acschembio.1c00524 PMID: 34592097
  82. Thell, K.; Hellinger, R.; Sahin, E.; Michenthaler, P.; Gold-Binder, M.; Haider, T.; Kuttke, M.; Liutkevičiūtė, Z.; Göransson, U.; Gründemann, C.; Schabbauer, G.; Gruber, C.W. Oral activity of a nature-derived cyclic peptide for the treatment of multiple sclerosis. Proc. Natl. Acad. Sci., 2016, 113(15), 3960-3965. doi: 10.1073/pnas.1519960113 PMID: 27035952
  83. Dayani, L.; Dinani, M.S.; Aliomrani, M.; Hashempour, H.; Varshosaz, J.; Taheri, A. Immunomodulatory effects of cyclotides isolated from Viola odorata in an experimental autoimmune encephalomyelitis animal model of multiple sclerosis. Mult. Scler. Relat. Disord., 2022, 64, 103958-103972. doi: 10.1016/j.msard.2022.103958 PMID: 35716476
  84. (a) Liddicoat, A.M.; Lavelle, E.C. Modulation of innate immunity by cyclosporine A. Biochem. Pharmacol., 2019, 163, 472-480. doi: 10.1016/j.bcp.2019.03.022 PMID: 30880061; (b) Patel, D.; Wairkar, S. Recent advances in cyclosporine drug delivery: challenges and opportunities. Drug Deliv. Transl. Res., 2019, 9(6), 1067-1081. doi: 10.1007/s13346-019-00650-1 PMID: 31144214
  85. Fervenza, F.C.; Appel, G.B.; Barbour, S.J.; Rovin, B.H.; Lafayette, R.A.; Aslam, N.; Jefferson, J.A.; Gipson, P.E.; Rizk, D.V.; Sedor, J.R.; Simon, J.F.; McCarthy, E.T.; Brenchley, P.; Sethi, S.; Avila-Casado, C.; Beanlands, H.; Lieske, J.C.; Philibert, D.; Li, T.; Thomas, L.F.; Green, D.F.; Juncos, L.A.; Beara-Lasic, L.; Blumenthal, S.S.; Sussman, A.N.; Erickson, S.B.; Hladunewich, M.; Canetta, P.A.; Hebert, L.A.; Leung, N.; Radhakrishnan, J.; Reich, H.N.; Parikh, S.V.; Gipson, D.S.; Lee, D.K.; da Costa, B.R.; Jüni, P.; Cattran, D.C. Rituximab or cyclosporine in the treatment of membranous nephropathy. N. Engl. J. Med., 2019, 381(1), 36-46. doi: 10.1056/NEJMoa1814427 PMID: 31269364
  86. Costa, L.; Sousa, E.; Fernandes, C. Cyclic peptides in pipeline: what future for these great molecules? Pharmaceuticals, 2023, 16(7), 996. doi: 10.3390/ph16070996 PMID: 37513908
  87. Dhillon, S.; Keam, S.J. Bremelanotide: First approval. Drugs, 2019, 79(14), 1599-1606. doi: 10.1007/s40265-019-01187-w PMID: 31429064
  88. Scheinberg, A.R.; Martin, P.; Turkeltaub, J.A. Terlipressin in the management of liver disease. Expert Opin. Pharmacother., 2023, 24(15), 1665-1671. doi: 10.1080/14656566.2023.2244427 PMID: 37535437
  89. Markham, A. Setmelanotide: First approval. Drugs, 2021, 81(3), 397-403. doi: 10.1007/s40265-021-01470-9 PMID: 33638809
  90. Duggan, S. Vosoritide: First approval. Drugs, 2021, 81(17), 2057-2062. doi: 10.1007/s40265-021-01623-w PMID: 34694597
  91. Hoy, S.M. Pegcetacoplan: First approval. Drugs, 2021, 81(12), 1423-1430. doi: 10.1007/s40265-021-01560-8 PMID: 34342834
  92. Heo, Y.A. Voclosporin: First approval. Drugs, 2021, 81(5), 605-610. doi: 10.1007/s40265-021-01488-z PMID: 33788181
  93. Keam, S.J. Lutetium Lu 177 vipivotide tetraxetan: First approval. Mol. Diagn. Ther., 2022, 26(4), 467-475. doi: 10.1007/s40291-022-00594-2 PMID: 35553387
  94. Lamb, Y.N. Pacritinib: First approval. Drugs, 2022, 82(7), 831-838. doi: 10.1007/s40265-022-01718-y PMID: 35567653
  95. Syed, Y.Y. Rezafungin: First approval. Drugs, 2023, 83(9), 833-840. doi: 10.1007/s40265-023-01891-8 PMID: 37212966
  96. Boivin-Jahns, V.; Uhland, K.; Holthoff, H.P.; Beyersdorf, N.; Kocoski, V.; Kerkau, T.; Münch, G.; Lohse, M.J.; Ungerer, M.; Jahns, R. Cyclopeptide COR-1 to treat beta1-adrenergic receptor antibody-induced heart failure. PLoS One, 2018, 13(8), e0201160. doi: 10.1371/journal.pone.0201160 PMID: 30125285
  97. Anup, K.; Harri, J.; Raed Moh’d Taiseer, A-R.; Anwaar, S.; Milind, A.P.; Anusha, C.; Timothy, S.; Sean, K.; Mazin Mazin, A-K.; John, A.; Benjamin, M.; Samuel, L.; Mojtaba, O.; Amit, R.; Scott James, W.; Subhrajit, S.; Prasad, D.; Rashna, M.; Weijing, S.; Joaquina Celebre, B. Phase Ib/IIa trial of CEND-1 in combination with neoadjuvant FOLFIRINOX-based therapies in pancreatic, colorectal, and appendiceal cancers (CENDIFOX). J. Clin. Oncol., 2022, 40(16)
  98. Mastellos, D.C.; Skendros, P.; Lambris, J.D. Is complement the culprit behind COVID-19 vaccine-related adverse reactions? J. Clin. Invest., 2021, 131(11), e151092. doi: 10.1172/JCI151092 PMID: 33945504
  99. (a) Zhuang, L.; Huang, S.; Liu, W.Q.; Karim, A.S.; Jewett, M.C.; Li, J. Total in vitro biosynthesis of the nonribosomal macrolactone peptide valinomycin. Metab. Eng., 2020, 60, 37-44. doi: 10.1016/j.ymben.2020.03.009 PMID: 32224263; (b) Zhang, D.; Ma, Z.; Chen, H.; Lu, Y.; Chen, X. Valinomycin as a potential antiviral agent against coronaviruses: A review. Biomed. J., 2020, 43(5), 414-423. doi: 10.1016/j.bj.2020.08.006 PMID: 33012699
  100. O’Shaughnessy, J.; Kaklamani, V.; Kalinsky, K. Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer. Future Oncol., 2019, 15(14), 1641-1653. doi: 10.2217/fon-2018-0936 PMID: 30892083
  101. Barth, P.; Bruijnzeel, P.; Wach, A.; Sellier Kessler, O.; Hooftman, L.; Zimmermann, J.; Naue, N.; Huber, B.; Heimbeck, I.; Kappeler, D.; Timmer, W.; Chevalier, E. Single dose escalation studies with inhaled POL6014, a potent novel selective reversible inhibitor of human neutrophil elastase, in healthy volunteers and subjects with cystic fibrosis. J. Cyst. Fibros., 2020, 19(2), 299-304. doi: 10.1016/j.jcf.2019.08.020 PMID: 31501052
  102. Guerlavais, V.; Sawyer, T.K.; Carvajal, L.; Chang, Y.S.; Graves, B.; Ren, J.G.; Sutton, D.; Olson, K.A.; Packman, K.; Darlak, K.; Elkin, C.; Feyfant, E.; Kesavan, K.; Gangurde, P.; Vassilev, L.T.; Nash, H.M.; Vukovic, V.; Aivado, M.; Annis, D.A. Discovery of sulanemadlin (ALRN-6924), the first cell-permeating, stabilized α-helical peptide in clinical development. J. Med. Chem., 2023, 66(14), 9401-9417. doi: 10.1021/acs.jmedchem.3c00623 PMID: 37439511
  103. Howard, J.F., Jr; Bresch, S.; Genge, A.; Hewamadduma, C.; Hinton, J.; Hussain, Y.; Juntas-Morales, R.; Kaminski, H.J.; Maniaol, A.; Mantegazza, R.; Masuda, M.; Sivakumar, K.; Śmiłowski, M.; Utsugisawa, K.; Vu, T.; Weiss, M.D.; Zajda, M.; Boroojerdi, B.; Brock, M.; de la Borderie, G.; Duda, P.W.; Lowcock, R.; Vanderkelen, M.; Leite, M.I.; Sembinelli, D.; Teitelbaum, J.; Nicolle, M.; Bernard, E.; Svahn, J.; Spinazzi, M.; Stojkovic, T.; Demeret, S.; Weiss, N.; Le Guennec, L.; Messai, S.; Tranchant, C.; Nadaj-Pakleza, A.; Chanson, J-B.; Suliman, M.; Zaidi, L.; Tard, C.; Lecointe, P.; Zschüntzsch, J.; Schmidt, J.; Glaubitz, S.; Zeng, R.; Scholl, M.; Kowarik, M.; Ziemann, U.; Krumbholz, M.; Martin, P.; Ruschil, C.; Dünschede, J.; Kemmner, R.; Rumpel, N.; Berger, B.; Totzeck, A.; Hagenacker, T.; Stolte, B.; Iorio, R.; Evoli, A.; Falso, S.; Antozzi, C.; Frangiamore, R.; Vanoli, F.; Rinaldi, E.; Deguchi, K.; Minami, N.; Nagane, Y.; Suzuki, Y.; Ishida, S.; Suzuki, S.; Nakahara, J.; Nagaoka, A.; Yoshimura, S.; Konno, S.; Tsuya, Y.; Uzawa, A.; Kubota, T.; Takahashi, M.; Okuno, T.; Murai, H.; Gilhus, N.E.; Boldingh, M.; Rønning, T.H.; Chyrchel-Paszkiewicz, U.; Kumor, K.; Zielinski, T.; Banaszkiewicz, K.; Błaż, M.; Kłósek, A.; Świderek-Matysiak, M.; Szczudlik, A.; Paśko, A.; Szczechowski, L.; Banach, M.; Ilkowski, J.; Kapetanovic Garcia, S.; Ortiz Bagan, P.; Belén Cánovas Segura, A.; Turon Sans, J.; Vidal Fernandez, N.; Cortes Vicente, E.; Rodrigo Armenteros, P.; Ashraghi, M.; Cavey, A.; Haslam, L.; Emery, A.; Liow, K.; Yegiaian, S.; Barboi, A.; Vazquez, R.M.; Lennon, J.; Pascuzzi, R.M.; Bodkin, C.; Guingrich, S.; Comer, A.; Bromberg, M.; Janecki, T.; Saba, S.; Tellez, M.; Elsheikh, B.; Freimer, M.; Heintzman, S.; Govindarajan, R.; Guptill, J.; Massey, J.M.; Juel, V.; Gonzalez, N.; Habib, A.A.; Mozaffar, T.; Korb, M.; Goyal, N.; Machemehl, H.; Manousakis, G.; Allen, J.; Harper, E.; Farmakidis, C.; Saavedra, L.; Dimachkie, M.; Pasnoor, M.; Akhter, S.; Beydoun, S.; McIlduff, C.; Nye, J.; Roy, B.; Munro Sheldon, B.; Nowak, R.; Barnes, B.; Rivner, M.; Suresh, N.; Shaw, J.; Harvey, B.; Lam, L.; Thomas, N.; Chopra, M.; Traub, R.E.; Jones, S.; Wagoner, M.; Smajic, S.; Aly, R.; Katz, J.; Chen, H.; Miller, R.G.; Jenkins, L.; Khan, S.; Khatri, B.; Sershon, L.; Pavlakis, P.; Holzberg, S.; Li, Y.; Caristo, I.B.; Marquardt, R.; Hastings, D.; Rube, J.; Lisak, R.P.; Choudhury, A.; Ruzhansky, K.; Sachdev, A.; Shin, S.; Bratton, J.; Fetter, M.; McKinnon, N.; McKinnon, J.; Sissons-Ross, L.; Sahu, A.; Distad, B.J. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): A randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol., 2023, 22(5), 395-406. doi: 10.1016/S1474-4422(23)00080-7 PMID: 37059508
  104. Mammen, A.L.; Amato, A.A.; Dimachkie, M.M.; Chinoy, H.; Hussain, Y.; Lilleker, J.B.; Pinal-Fernandez, I.; Allenbach, Y.; Boroojerdi, B.; Vanderkelen, M.; Delicha, E.M.; Koendgen, H.; Farzaneh-Far, R.; Duda, P.W.; Sayegh, C.; Benveniste, O.; Amato, A.A.; Benveniste, O.; Biliciler, S.; Chinoy, H.; Dimachkie, M.M.; Edmundson, C.; Freimer, M.; Geraci, A.; Hussain, Y.; Machado, P.; Mammen, A.L.; Mozaffar, T.; Soltanzadeh, P.; Suresh, N.; van der Kooi, A.; Allenbach, Y.; Appleby, M.; Barohn, R.J.; Champtiaux, N.; Doughty, C.; Farias, J.; Farmakidis, C.; Habib, A.A.; Karam, C.; Lilleker, J.; Lorusso, S.; Pasnoor, M.; Pinal-Fernandez, I.; Querin, G.; Raaphorst, J.; Ransley, G.; Saba, S.; Sheikh, K.; Snedden, A.; Statland, J.; Vu, T. Zilucoplan in immune-mediated necrotising myopathy: A phase 2, randomised, double-blind, placebo-controlled, multicentre trial. Lancet Rheumatol., 2023, 5(2), e67-e76. doi: 10.1016/S2665-9913(23)00003-6 PMID: 36923454
  105. Cook, N.; Banerji, U.; Evans, J.; Biondo, A.; Germetaki, T.; Randhawa, M.; Godfrey, L.; Leslie, S.; Jeffrey, P.; Rigby, M.; Bennett, G.; Blakemore, S.; Koehler, M.; Niewiarowski, A.; Pittman, M.; Symeonides, S.N. 464PPharmacokinetic (PK) assessment of BT1718: A phase I/II a study of BT1718, a first in class bicycle toxin conjugate (BTC), in patients (pts) with advanced solid tumours. Ann. Oncol., 2019, 30(5)
  106. Capucine, B.; Vincent, G.; Irene, B.; Bernard, D.; Antoine, I.; Sophie, C.; Gerald Steven, F.; Andrea, N.; Oscar, R.; Louise, C.; Elisa, F.; Loic, V.; Sebastien, H.; Amy, D.; Cong, X.; Hongmei, X.; Rajiv, S.; Dominic, S.; Meredith, M. BT8009-100: A phase I/II study of novel bicyclic peptide and MMAE conjugate BT8009 in patients (pts) with advanced malignancies associated with nectin-4 expression, including urothelial cancer (UC). J. Clin. Oncol., 2023, 41(6), 498-498.
  107. Bendell, J.C.; Wang, J.S.Z.; Bashir, B.; Richardson, D.L.; Bennett, G.; Campbell, C.; Hennessy, M.G.; Jeffrey, P.; Kirui, J.; Mahnke, L.; Shapiro, G. BT5528-100 phase I/II study of the safety, pharmacokinetics, and preliminary clinical activity of BT5528 in patients with advanced malignancies associated with EphA2 expression. J. Clin. Oncol., 2020, 38(15_suppl), TPS3655. doi: 10.1200/JCO.2020.38.15_suppl.TPS3655
  108. Kyriakos, P.P.; Afshin, D.; Amy, D.; Sandra, H.; Sally, W.; Punit, U.; Heather, C.; Kristen, H.; Roshawn, W.; Sebastien, H.; Dominic, S.; Jordi Rodon, A. A combined phase I/II study of a novel bicycle tumor-targeted immune cell agonist BT7480 in patients with nectin-4 associated advanced malignancies. J. Clin. Oncol., 2022, 40(16)
  109. Wyer, S.; Townsend, D.M.; Ye, Z.; Kourtidis, A.; Choo, Y.M.; de Barros, A.L.B.; Donia, M.S.; Hamann, M.T. Recent advances and limitations in the application of kahalalides for the control of cancer. Biomed. Pharmacother., 2022, 148, 112676-112685. doi: 10.1016/j.biopha.2022.112676 PMID: 35149387
  110. a) Ling, Y.H.; Aracil, M.; Zou, Y.; Yuan, Z.; Lu, B.; Jimeno, J.; Cuervo, A.M.; Perez-Soler, R. PM02734 (elisidepsin) induces caspase-independent cell death associated with features of autophagy, inhibition of the Akt/mTOR signaling pathway, and activation of death-associated protein kinase. Clin. Cancer Res., 2011, 17(16), 5353-5366. doi: 10.1158/1078-0432.CCR-10-1948 PMID: 21690574; b) Martín-Algarra, S.; Espinosa, E.; Rubió, J.; López, J.J.L.; Manzano, J.L.; Carrión, L.A.; Plazaola, A.; Tanovic, A.; Paz-Ares, L. Phase II study of weekly Kahalalide F in patients with advanced malignant melanoma. Eur. J. Cancer, 2009, 45(5), 732-735. doi: 10.1016/j.ejca.2008.12.005 PMID: 19186051
  111. Ballantyne, C.M.; Banka, P.; Mendez, G.; Garcia, R.; Rosenstock, J.; Rodgers, A.; Mendizabal, G.; Mitchel, Y.; Catapano, A.L. Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616. J. Am. Coll. Cardiol., 2023, 81(16), 1553-1564. doi: 10.1016/j.jacc.2023.02.018 PMID: 36889610
  112. Tanada, M.; Tamiya, M.; Matsuo, A.; Chiyoda, A.; Takano, K.; Ito, T.; Irie, M.; Kotake, T.; Takeyama, R.; Kawada, H.; Hayashi, R.; Ishikawa, S.; Nomura, K.; Furuichi, N.; Morita, Y.; Kage, M.; Hashimoto, S.; Nii, K.; Sase, H.; Ohara, K.; Ohta, A.; Kuramoto, S.; Nishimura, Y.; Iikura, H.; Shiraishi, T. Development of orally bioavailable peptides targeting an intracellular protein: From a hit to a clinical KRAs inhibitor. J. Am. Chem. Soc., 2023, 145(30), 16610-16620. doi: 10.1021/jacs.3c03886 PMID: 37463267
  113. Saharan, R.; Kumar, S.; Khokra, S.L. A comprehensive review on therapeutic potentials of natural cyclic peptides. Curr. Nutr. Food Sci., 2021, 18, 441-449.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers